A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT04394650. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT04394650
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Interventions
- CC-98633 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2020
- Primary completion
- Jul 2, 2024
- Completion
- Jul 2, 2024
- Last update posted
- Jul 25, 2024
2020 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 103 | Birmingham | Alabama | 35233 | — |
| Local Institution - 111 | Phoenix | Arizona | 85054 | — |
| Local Institution - 110 | Stanford | California | 94305 | — |
| Local Institution - 107 | Chicago | Illinois | 60637 | — |
| Local Institution - 101 | Westwood | Kansas | 66205-2003 | — |
| Local Institution - 109 | Rochester | Minnesota | 55905 | — |
| Local Institution - 106 | Buffalo | New York | 14263 | — |
| Local Institution - 104 | New York | New York | 10029 | — |
| Local Institution - 102 | New York | New York | 10065 | — |
| Local Institution - 108 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 105 | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04394650, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2024 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04394650 live on ClinicalTrials.gov.